Jove
Visualize
联系我们

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Cognitive Trajectories from Preclinical Alzheimer's Disease to Dementia.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Alzheimer's Imaging Consortium.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Donanemab in early symptomatic Alzheimer's disease: results from the TRAILBLAZER-ALZ 2 long-term extension.

The journal of prevention of Alzheimer's disease·2025
Same author

Estimating the time course of biomarker changes in Alzheimer's disease.

Brain : a journal of neurology·2025
Same author

A systematic review and meta-analysis of real-world data predictors for conversion to progressive multiple sclerosis.

Multiple sclerosis and related disorders·2025
Same author

IPECAD Modeling Workshop 2023 Cross-Comparison Challenge on Cost-Effectiveness Models in Alzheimer's Disease.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2024
Same journal

Evidence for progressive neurodegeneration in iatrogenic cerebral amyloid angiopathy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Human brain connectome profiles mediate the relationship between pathology burden and clinical phenotypes in Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Kat5 cKO mouse replicates biological domain signatures associated with Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Evaluation of CSF and plasma tau species as fluid surrogate candidates for tau PET in prodromal to moderate Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Associations of self-reported obstructive sleep apnea with cognition and dementia risk in cognitively unimpaired middle-aged adults.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Inflammation profiles in Alzheimer's disease relate to cognition and neurodegeneration.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Lars Lau Raket1

  • 1Clinical Memory Research Unit, Lund University, Malmö, Sweden.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 24, 2025
PubMed
概括
此摘要是机器生成的。

结合多个生物标志物和临床措施,可以改善阿尔茨海默病 (AD) 的病期. 新的方法显示,在AD连续体中,比标准的粉样蛋白和粉样蛋白PET时钟更好地对齐,而这些时钟可能会过度匹配. 年龄调整可以提高分期的准确性.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学领域:

  • 神经科学是一个神经科学.
  • 生物标志物研究 生物标志物研究
  • 老年学是指老年学的学科.

背景情况:

  • 阿尔茨海默病 (AD) 是一种复杂的神经退行性疾病,导致渐进性的认知能力下降.
  • 了解AD的多个时间尺度对于诊断和治疗至关重要.
  • 本研究将粉样蛋白和蛋白PET时钟与新的多生物标志物分期方法进行比较.

研究的目的:

  • 为了比较粉样和PET时钟的性能与新的分期方法.
  • 评估结合多个生物标志物和临床措施的分期方法.
  • 为了评估整个阿尔茨海默病连续性的分期准确性.

主要方法:

  • 利用了来自1064名Aβ阳性和384名Aβ阴性参与者的纵向数据.
  • 衍生出粉样蛋白和PET时钟,并采用非线性混合效应建模用于替代阶段.
  • 使用与临床,流体和成像生物标志物的斯皮尔曼相关性评估对齐质量;研究年龄影响.

主要成果:

  • 多种生物标志物 (粉样PET,质PET,认知) 的分期显示出比PET时钟更广泛的灵敏度和更好的生物标志物对齐.
  • 在临床前/临床前阶段,粉样蛋白PET时钟表表现良好;除了后期阶段,粉样蛋白PET时钟表效率较低.
  • 年龄调整改善了所有分期方法的对齐质量.

结论:

  • 整合多个生物标志物和临床数据可以提高阿尔茨海默病的病期.
  • 粉样蛋白和蛋白PET时钟是有价值的,但在整个AD连续的分期方面存在局限性.
  • 未来的PET时钟应该使用先进的统计模型,并进行调整和年龄调整,以避免过度装配.